Priya Pancholi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Priya Pancholi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Neal Rosen
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, USA
13 shared publications - Afsar Barlas
Molecular Cytology Core, Memorial Sloan Kettering Cancer Center, New York, New York
12 shared publications - Elisa de Stanchina
Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA
12 shared publications - Eric Chan
Molecular Cytology Core, Memorial Sloan Kettering Cancer Center, New York, New York
12 shared publications - Hongyan Li
Memorial Sloan Kettering Cancer Center 3 New York, New York
12 shared publications - Jacob A. Boyer
Ludwig Cancer Institute, Princeton Branch, Princeton University, Princeton, New Jersey
12 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition